FULC Company Profile and Key Details

Q: Who are the executives of FULC?

Prof. Jeannie T. Lee M.D., Ph.D.FounderMr. Alexander C. SapirChief Executive Officer, Pres & DirectorDr. Jeffrey W. Jacobs Ph.D.Chief Scientific OfficerDr. Bradley E. Bernstein M.D., Ph.D.FounderMr. Bryan E. StuartPres, Chief Executive Officer & DirectorMr. Mel HayesChief Operating OfficerDr. Judith A. Dunn Ph.D.Interim Chief Medical OfficerMr. Gregory TourangeauController & Principal Accounting OfficerMs. Esther P. RajaveluChief Financial Officer & TreasurerDr. Rudolf Jaenisch M.D., Ph.D.FounderDr. Michael R. GreenFounderMr. Alan A. Musso C.M.A., C.P.A., CPAChief Financial OfficerDr. Danny ReinbergFounderMr. Alan A. Musso C.M.A., CPA, CPAChief Financial OfficerDr. Robert J. Gould Ph.D.Pres, Interim Chief Executive Officer & DirectorMr. Curtis G. Oltmans J.D.Senior Vice President, Chief Legal Officer & Corporation Sec.

NASDAQ : FULC

Fulcrum Therapeutics

$3.61

-0.15-3.99%

At Close 4:00 PM

59.51

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Fulcrum Therapeutics, Inc. (FULC) stock declined over -3.99%, trading at $3.61 on NASDAQ, down from the previous close of $3.76. The stock opened at $3.78, fluctuating between $3.60 and $3.86 in the recent session.

Stock Snapshot

3.76

Prev. Close

195.34M

Market Cap

3.6

Day Low

-3.14

P/E Ratio

-1.15

EPS (TTM)

-1.48

Cash Flow per Share

3.78

Open

54.11M

Number of Shares

3.86

Day High

88.64%

Free Float in %

3.8

Book Value

2.74M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 25, 2026	3.78	3.86	3.60	3.61	3.1M
Jun 24, 2026	3.85	4.01	3.68	3.76	3.67M
Jun 23, 2026	3.69	3.89	3.69	3.85	2.81M
Jun 22, 2026	3.69	3.89	3.63	3.77	2.87M
Jun 18, 2026	3.56	3.71	3.46	3.70	6.1M
Jun 17, 2026	3.49	3.61	3.45	3.50	10.47M
Jun 16, 2026	3.52	3.64	3.43	3.46	6.03M
Jun 15, 2026	3.52	3.62	3.47	3.51	3.33M
Jun 12, 2026	3.56	3.61	3.43	3.45	1.34M
Jun 11, 2026	3.56	3.61	3.46	3.55	2.5M
Jun 10, 2026	3.50	3.64	3.34	3.51	2.46M
Jun 09, 2026	3.49	3.62	3.36	3.52	3.98M
Jun 08, 2026	3.51	3.63	3.36	3.44	3.31M
Jun 05, 2026	3.36	3.70	3.30	3.69	3.95M
Jun 04, 2026	3.29	3.39	3.21	3.37	4.81M
Jun 03, 2026	3.10	3.27	3.10	3.22	5.59M
Jun 01, 2026	7.02	7.02	6.38	6.42	2.66M
May 29, 2026	6.83	7.07	6.71	6.92	390.74K
May 28, 2026	6.78	6.83	6.68	6.82	313.65K
May 27, 2026	6.76	7.00	6.74	6.78	325.79K

Contact Details

Cambridge, MA 02139

United States

https://www.fulcrumtx.com 617 651 8851

About Company

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.

Stock Peers

ARGX

36.15+4.24%

argenx SE$888.65 REGN

-3.29-0.53%

Regeneron Pharmaceuticals, Inc.$620.14 UTHR

-6.51-1.18%

United Therapeutics Corporation$543.39 MDGL

4.03+0.79%

Madrigal Pharmaceuticals, Inc.$513.79 VRTX

4.98+1.05%

Vertex Pharmaceuticals Incorporated$480.18 KRYS

12.3+3.54%

Krystal Biotech, Inc.$359.93 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

18.92+6.12%

Praxis Precision Medicines, Inc.$327.86 LGND

11.01+3.86%

Ligand Pharmaceuticals Incorporated$295.92 ALNY

-0.89-0.30%

Alnylam Pharmaceuticals, Inc.$293.17

Frequently Asked Questions

What is the current Fulcrum Therapeutics, Inc. (FULC) stock price?

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) stock price is $3.61 in the last trading session. During the trading session, FULC stock reached the peak price of $3.86 while $3.60 was the lowest point it dropped to. The percentage change in FULC stock occurred in the recent session was -3.99% while the dollar amount for the price change in FULC stock was - $0.15.

FULC's industry and sector of operation?

The NASDAQ listed FULC is part of Biotechnology industry that operates in the broader Healthcare sector. Fulcrum Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of FULC?

Prof. Jeannie T. Lee M.D., Ph.D.
Founder
Mr. Alexander C. Sapir
Chief Executive Officer, Pres & Director
Dr. Jeffrey W. Jacobs Ph.D.
Chief Scientific Officer
Dr. Bradley E. Bernstein M.D., Ph.D.
Founder
Mr. Bryan E. Stuart
Pres, Chief Executive Officer & Director
Mr. Mel Hayes
Chief Operating Officer
Dr. Judith A. Dunn Ph.D.
Interim Chief Medical Officer
Mr. Gregory Tourangeau
Controller & Principal Accounting Officer
Ms. Esther P. Rajavelu
Chief Financial Officer & Treasurer
Dr. Rudolf Jaenisch M.D., Ph.D.
Founder
Dr. Michael R. Green
Founder
Mr. Alan A. Musso C.M.A., C.P.A., CPA
Chief Financial Officer
Dr. Danny Reinberg
Founder
Mr. Alan A. Musso C.M.A., CPA, CPA
Chief Financial Officer
Dr. Robert J. Gould Ph.D.
Pres, Interim Chief Executive Officer & Director
Mr. Curtis G. Oltmans J.D.
Senior Vice President, Chief Legal Officer & Corporation Sec.

How FULC did perform over past 52-week?

FULC's closing price is 27.56% higher than its 52-week low of $2.83 where as its distance from 52-week high of $15.74 is -77.06%.

How many employees does FULC have?

Number of FULC employees currently stands at 45.

Link for FULC official website?

Official Website of FULC is: https://www.fulcrumtx.com

How do I contact FULC?

FULC could be contacted at phone 617 651 8851 and can also be accessed through its website. FULC operates from 26 Landsdowne Street, Cambridge, MA 02139, United States.

How many shares of FULC are traded daily?

FULC stock volume for the day was 2.74M shares. The average number of FULC shares traded daily for last 3 months was 2.14M.

What is the market cap of FULC currently?

The market value of FULC currently stands at $195.34M with its latest stock price at $3.61 and 54.11M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	45
Beta	2.92
Sales or Revenue	$2.81M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	45
Beta	2.92
Sales or Revenue	$2.81M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

FULC Company Profile and Key Details

Fulcrum Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Shareholding & Insider Activity

Valuation Metrics

Price Forecast & Outlook

Key Takeaways